Amavea – Associationfor MeningiomasDue toandCyproterone Acetate, Victim Support Considerationof OtherMolecules

Accueil > Documentation > Stabilisation de la croissance et régression des méningiomes après l’arrêt de l’acétate de cyprotérone (Androcur) : une série de cas de 12 patients.

Stabilization of growth and regression of meningiomas after stopping cyproterone acetate (Androcur): a series of cases of 12 patients.

Stabilization of growth and regression of meningiomas after stopping cyproterone acetate (Androcur): a series of cases of 12 patients.

ETUDE DU Pr SEBASTIEN FROELICH
(rappel de l’existence de cette étude dans un tweet de ce jour ):
Stabilisation de la croissance et régression des méningiomes après l’arrêt de l’acétate de cyprotérone: une série de cas de 12 patients.
Bernat AL et al. Acta Neurochir (Wien). 2015.

Context: the relationship between meningiomas and exogenous sex hormones is well known, but cyproterone acetate (CA), a progesterone agonist, seems to have a stronger influence on tumor growth.

Objective: to show the close relationship between AC treatment and the growth of meningioma.

Methods: Since 2010, all patients referred to our clinic for suspicion of meningiom have been questioned specifically on the supply of exogenous sex hormones and more specifically on the supply of AC. Twelve patients with one or more meningiomas and treated by CA have been identified. It was arrested in all cases. The tumor volumes and diameters were measured on series in series and compared to the last MRI before the withdrawal of AC.

Results: Ten patients with multiple tumors have taken the medication for longer (an average of 20.4 years) than the two patients with a tumor (10 years). Two patients with multiple tumors underwent surgery due to a rapid decrease in visual acuity at the time of diagnosis. AC cessation led to a narrowing of the tumor in 11 patients and a cessation of tumor growth in a [the average reduction in the tumor volume was approximately 10 cm (3) / year; (0.00; 76)]. There was no regrowth during an average monitoring period of 12 months (interval: 5-35).

CONCLUSION: Pour les patients diagnostiqués avec un méningiome et traités par CA, le retrait des médicaments suivi d’une observation devrait être la première ligne de traitement. Des précautions doivent être prises lors de l’utilisation à long terme de fortes doses d’AC, et des IRM cérébrales en série doivent être envisagées après plusieurs années d’AC.

https://www.ncbi.nlm.nih.gov/m/pubmed/26264069/?i=22&from=bernat%20al

Find other articles from Amavea here

Discover other articles

Back to articles